Expert-led podcast: Navigating the assessment and treatment of CTCL
Prescribing information is available at the top of the page.
Listen to clinical experts explore the heterogeneous nature of CTCL, defining the subtypes MF, pcALCL and SS. Professor Whittaker, Consultant Dermatologist at Guy’s and St. Thomas’ NHS Foundation Trust, and
Dr Osborne, Consultant Haematologist at Newcastle Hospitals NHS Foundation Trust, explain the importance of testing for CD30 expression when identifying systemic treatment options for CTCL patients, while also considering the criterion of the Cancer Drugs Fund in England.
This podcast also discusses the use of ADCETRIS® (brentuximab vedotin) as a treatment option for adult patients with CD30+ CTCL after at least 1 prior systemic therapy, describing the efficacy and safety results from the ALCANZA trial1 to support the use of ADCETRIS as monotherapy in this setting.
CTCL, cutaneous T-cell lymphoma; MF, mycosis fungoides; pcALCL, primary cutaneous anaplastic large cell lymphoma; SS, Sézary syndrome.
1. Prince HM et al. Lancet 2017;390:555–566.
To enjoy the full experience of OncoConnect, including the ability to like and bookmark content for easy access via your account section, please register or login now.
